Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Bibtex

@article{13ef977a5e03417b854d7363405d0f12,
title = "Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture",
abstract = "The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated, in preparation for a Phase I clinical trial of boron neutron capture therapy. BSH was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.",
keywords = "Boron neutron capture therapy, glioma, BSH",
author = "D Gabel and D Preusse and D Haritz and F Grochulla and K Haselsberger and H Fankhauser and Crister Ceberg and Peters, {H D} and U Klotz",
year = "1997",
doi = "10.1007/BF01411994",
language = "English",
volume = "139",
pages = "606--612",
journal = "Acta Neurochirurgica",
issn = "0001-6268",
publisher = "Springer",
number = "7",

}